Q32 Bio Inc.(US:QTTB)2025-03-11 11:03Financial Performance - Cash and cash equivalents were $78.0 million as of December 31, 2024, expected to fund operations into the second half of 2026[9] - Net loss for Q4 2024 was $14.2 million, or $1.16 per share, significantly improved from a net loss of $27.1 million, or $76.39 per share, in Q4 2023[9] - Total operating expenses for Q4 2024 were $14.5 million, compared to $11.1 million in Q4 2023[14] - Total assets increased to $92.3 million as of December 31, 2024, up from $47.1 million in 2023[16] Research and Development - Research and development expenses increased to $10.5 million for Q4 2024, up from $8.3 million in Q4 2023, primarily due to higher clinical trial costs[9] - Bempikibart demonstrated clinically meaningful activity in a difficult-to-treat patient population, with continued effects observed after treatment cessation[3] - The Phase 2a Part A trial of bempikibart showed a deepening response in patients, with all 12 responding patients maintaining or achieving further hair growth post-treatment[4] - The company plans to initiate an open-label extension (OLE) for bempikibart in the first half of 2025, based on strong patient demand and ongoing responses[4] - SIGNAL-AA Part B is on track to initiate dosing in the first half of 2025, with topline data expected in the first half of 2026[4] General and Administrative Expenses - General and administrative expenses rose to $4.0 million in Q4 2024, compared to $2.8 million in Q4 2023, driven by increased stock-based compensation and public company-related costs[9]